ClinVar Miner

Submissions for variant NM_000268.4(NF2):c.1021C>T (p.Arg341Ter)

dbSNP: rs74315499
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 6
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV000003453 SCV000553677 pathogenic Neurofibromatosis, type 2 2023-07-28 criteria provided, single submitter clinical testing This sequence change creates a premature translational stop signal (p.Arg341*) in the NF2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in NF2 are known to be pathogenic (PMID: 9643284, 16983642). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with neurofibromatosis type 2 (PMID: 7913580, 8379998, 11809806, 12566519, 21671232). ClinVar contains an entry for this variant (Variation ID: 3292). For these reasons, this variant has been classified as Pathogenic.
GeneDx RCV000497720 SCV000589606 pathogenic not provided 2023-03-07 criteria provided, single submitter clinical testing Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss of function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 11809806, 15609345, 25525159, 8379998, 19234911, 9643284, 29130639, 12566519, 21671232, 7913580, 10790209, 7717450, 16630136, 30325044, 31273341, 32724039, 16983642, 33067351, 19249154)
Center for Human Genetics, Inc, Center for Human Genetics, Inc RCV000003453 SCV000782126 pathogenic Neurofibromatosis, type 2 2016-11-01 criteria provided, single submitter clinical testing
Genome-Nilou Lab RCV000003453 SCV002045425 pathogenic Neurofibromatosis, type 2 2021-11-07 criteria provided, single submitter clinical testing
Ambry Genetics RCV003278654 SCV004007056 pathogenic Hereditary cancer-predisposing syndrome 2023-06-13 criteria provided, single submitter clinical testing The p.R341* pathogenic mutation (also known as c.1021C>T), located in coding exon 11 of the NF2 gene, results from a C to T substitution at nucleotide position 1021. This changes the amino acid from an arginine to a stop codon within coding exon 11. This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). This alteration has been observed in at least one individual with a personal and/or family history that is consistent with NF2-related disease (Ambry internal data). This mutation has been identified in multiple patients meeting diagnostic criteria for neurofibromatosis type 2 (Walter J et al. Clin Neurol Neurosurg, 2009 Jun;111:454-9; Pemov A et al. Sci Rep, 2020 Jul;10:12563). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation.
OMIM RCV000003453 SCV000023611 pathogenic Neurofibromatosis, type 2 1994-08-01 no assertion criteria provided literature only

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.